ZLDPF:OTC-Zealand Pharma A/S (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 131.3925

Change

0.00 (0.00)%

Market Cap

USD 9.41B

Volume

N/A

Analyst Target

USD 36.83
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-08-02 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
UCBJY UCB SA ADR

N/A

USD 34.50B
UCBJF UCB SA

N/A

USD 34.43B
ARGNF argenx SE

N/A

USD 31.41B
GNMSF Genmab A/S

N/A

USD 17.62B
IVBIY IVBIY

N/A

USD 8.83B
SBMFF Sino Biopharmaceutical Limited

N/A

USD 7.30B
SBHMY Sino Biopharmaceutical Ltd ADR

N/A

USD 7.29B
WXXWY WuXi Biologics (Cayman) Inc

N/A

USD 5.87B
WXIBF WuXi Biologics

N/A

USD 5.87B
AKESF Akeso, Inc.

N/A

USD 5.35B

ETFs Containing ZLDPF

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 136.11% 92% A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 136.11% 92% A 95% A
Trailing 12 Months  
Capital Gain 293.16% 94% A 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 293.16% 94% A 97% N/A
Trailing 5 Years  
Capital Gain 481.38% 93% A 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 481.38% 93% A 96% N/A
Average Annual (5 Year Horizon)  
Capital Gain 47.38% 71% C- 76% C+
Dividend Return 47.38% 71% C- 75% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 87.47% 47% F 35% F
Risk Adjusted Return 54.17% 97% N/A 88% B+
Market Capitalization 9.41B 98% N/A 90% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector